Trials / Completed
CompletedNCT00993863
Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction
A Randomized, Single-Dose, Double-Blind, Active- and Placebo-Controlled Study of ADL5859 for the Treatment of Pain After Surgical Removal of Impacted Third Molars
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 201 (actual)
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the analgesic efficacy and safety of ADL5859 compared with placebo and an active control (ibuprofen) in subjects with acute dental pain after third molar extraction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | single dose |
| DRUG | ADL5859 30 mg | single dose |
| DRUG | ADL5859 100 mg | single dose |
| DRUG | ADL5859 200 mg | single dose |
| DRUG | ibuprofen 400 mg | single dose |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2007-09-01
- First posted
- 2009-10-14
- Last updated
- 2015-07-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00993863. Inclusion in this directory is not an endorsement.